Table III.
Clinicopathological characteristics based on staining intensity of LNα3, LNγ2 and expression patterns of LNγ2 (%).
| LNα3 | LNγ2 | Pattern of LN | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case (n=96) | Low | High | P-value | Low | High | P-value | B-type | C-type | M-type | P-value | |
| Gender | 0.356 | 0.152 | 0.364 | ||||||||
| M | 62 (64.6) | 18 (29.0) | 44 (71.0) | 27 (43.5) | 35 (56.5) | 11 (17.7) | 41 (66.1) | 10 (16.1) | |||
| F | 34 (35.4) | 13 (38.2) | 21 (61.8) | 20 (58.2) | 14 (41.2) | 10 (29.4) | 18 (52.9) | 6 (17.6) | |||
| Tumor size | 0.999 | 0.712 | 0.649 | ||||||||
| ≤2 cm | 7 (7.3) | 2 (28.6) | 5 (71.4) | 4 (57.1) | 3 (42.9) | 1 (14.3) | 4 (57.1) | 2 (28.6) | |||
| >2 cm | 89 (92.7) | 29 (32.6) | 60 (67.4) | 43 (48.3) | 46 (51.7) | 20 (22.5) | 55 (61.8) | 14 (15.7) | |||
| Location | 0.223 | 0.426 | 0.317 | ||||||||
| Head | 55 (57.3) | 15 (27.3) | 40 (72.7) | 25 (45.5) | 30 (54.5) | 9 (16.4) | 36 (65.5) | 10 (18.2) | |||
| Body or tail | 41 (42.7) | 16 (39.0) | 25 (61.0) | 22 (53.7) | 19 (46.3) | 12 (29.3) | 23 (56.1) | 6 (14.6) | |||
| Bile duct invasion | 0.464 | 0.792 | 0.792 | ||||||||
| Absent | 60 (62.5) | 21 (35.0) | 39 (65.0) | 30 (50.0) | 30 (50.0) | 15 (25.0) | 37 (61.7) | 8 (13.3) | |||
| Present | 36 (37.5) | 10 (27.8) | 26 (72.7) | 17 (47.2) | 19 (52.8) | 6 (16.7) | 22 (61.1) | 8 (22.2) | |||
| Duodenal invasion | 0.404 | 0.921 | 0.632 | ||||||||
| Absent | 69 (71.9) | 24 (77.4) | 45 (69.2) | 34 (49.3) | 35 (50.7) | 16 (23.2) | 43 (62.3) | 10 (14.5) | |||
| Present | 27 (28.1) | 7 (25.9) | 20 (74.1) | 13 (48.1) | 14 (51.9) | 5 (18.5) | 16 (59.3) | 6 (22.2) | |||
| Differentiation | 0.001 | 0.000 | 0.010 | ||||||||
| Well | 2 (2.1) | 2 (100.0) | 0 (0.0) | 2 (100.0) | 0 (0.0) | 2 (100.0) | 0 (0.0) | 0 (0.0) | |||
| Moderate | 37 (38.5) | 18 (48.6) | 19 (51.4) | 27 (73.0) | 10 (27.0) | 12 (32.4) | 21 (56.8) | 4 (10.8) | |||
| Poor | 57 (59.4) | 11 (19.3) | 46 (80.7) | 18 (31.6) | 39 (68.4) | 7 (12.3) | 38 (66.7) | 12 (21.1) | |||
| Lymph nodes invasion | 0.356 | 0.563 | 0.160 | ||||||||
| Absent | 34 (35.4) | 13 (38.2) | 21 (61.8) | 18 (52.9) | 16 (47.1) | 11 (32.4) | 19 (55.9) | 4 (11.8) | |||
| Present | 62 (64.6) | 18 (29.0) | 44 (71.0) | 29 (46.8) | 33 (53.2) | 10 (16.1) | 40 (64.5) | 12 (19.4) | |||
| Perineural invasion | 0.347 | 0.896 | 0.587 | ||||||||
| Absent | 28 (29.2) | 11 (39.3) | 17 (60.7) | 14 (50.0) | 14 (50.0) | 8 (28.6) | 16 (57.1) | 4 (14.3) | |||
| Present | 68 (70.8) | 20 (29.4) | 48 (70.6) | 33 (48.5) | 35 (51.5) | 13 (19.1) | 43 (63.2) | 12 (17.6) | |||
| Vascular invasion | 0.650 | 0.671 | 0.347 | ||||||||
| Absent | 78 (81.3) | 26 (33.3) | 52 (66.7) | 39 (50.0) | 39 (50.0) | 17 (21.8) | 50 (64.1) | 11 (14.1) | |||
| Present | 18 (18.8) | 5 (27.8) | 13 (72.2) | 8 (44.4) | 10 (55.6) | 4 (22.2) | 9 (50.0) | 5 (27.8) | |||
| Invasion to the serosa | 0.088 | 0.038 | 0.749 | ||||||||
| Absent | 53 (55.2) | 21 (39.6) | 32 (60.4) | 31 (58.5) | 22 (41.5) | 13 (24.5) | 32 (60.4) | 8 (15.1) | |||
| Present | 43 (44.8) | 10 (23.3) | 33 (76.7) | 16 (37.2) | 27 (62.8) | 8 (18.6) | 27 (62.8) | 8 (18.6) | |||
| Invasion to the serosa | 0.088 | 0.038 | 0.749 | ||||||||
| Absent | 53 (55.2) | 21 (39.6) | 32 (60.4) | 31 (58.5) | 22 (41.5) | 13 (24.5) | 32 (60.4) | 8 (15.1) | |||
| Present | 43 (44.8) | 10 (23.3) | 33 (76.7) | 16 (37.2) | 27 (62.8) | 8 (18.6) | 27 (62.8) | 8 (18.6) | |||
| Portal vein invasion | 0.971 | 0.564 | 0.864 | ||||||||
| Absent | 71 (74.0) | 23 (32.4) | 48 (67.6) | 36 (50.7) | 35 (49.3) | 16 (22.5) | 44 (62.0) | 11 (15.5) | |||
| Present | 25 (26.0) | 8 (32.0) | 17 (68.0) | 11 (44.0) | 14 (56.0) | 5 (20.0) | 15 (60.0) | 5 (20.0) | |||
| Margin status | 0.494 | 0.805 | 0.334 | ||||||||
| Absent | 85 (88.5) | 29 (34.1) | 56 (65.9) | 42 (49.4) | 43 (50.6) | 20 (23.5) | 50 (58.8) | 15 (17.6) | |||
| Present | 11 (11.5) | 2 (18.2) | 9 (81.8) | 5 (45.5) | 6 (54.5) | 1 (9.1) | 9 (81.8) | 1 (9.1) | |||
| Depth of invasion | 0.050 | 0.037 | 0.249 | ||||||||
| T1 | 6 (6.3) | 3 (50.0) | 3 (50.0) | 4 (66.7) | 2 (33.3) | 1 (16.7) | 3 (50.0) | 2 (33.3) | |||
| T2 | 39 (40.6) | 17 (43.6) | 22 (56.4) | 25 (64.1) | 14 (35.9) | 10 (25.6) | 27 (69.2) | 2 (5.1) | |||
| T3 | 31 (32.3) | 9 (29.0) | 22 (71.0) | 12 (38.7) | 19 (61.3) | 7 (22.6) | 18 (58.1) | 6 (19.4) | |||
| T4 | 20 (20.8) | 2 (10.0) | 18 (90.0) | 6 (30.0) | 14 (70.0) | 3 (15.0) | 11 (55.0) | 6 (30.0) | |||
| Hepatic metastasis | 0.999 | 0.357 | 0.031 | ||||||||
| Absent | 84 (87.5) | 27 (32.1) | 57 (67.9) | 43 (51.2) | 41 (48.8) | 18 (21.4) | 55 (65.5) | 11 (13.1) | |||
| Present | 12 (12.5) | 4 (33.3) | 8 (66.7) | 4 (33.3) | 8 (66.7) | 3 (25.0) | 4 (33.3) | 5 (41.7) | |||
| Stage | 0.014 | 0.014 | 0.103 | ||||||||
| 0+ I+ II | 64 (66.7) | 26 (40.6) | 38 (59.4) | 37 (57.8) | 27 (42.2) | 15 (23.4) | 42 (65.6) | 7 (10.9) | |||
| III + IV | 32 (33.3) | 5 (15.6) | 27 (84.4) | 10 (31.3) | 22 (68.8) | 6 (18.8) | 17 (53.1) | 9 (28.1) | |||
P-values were calculated using a χ2 (two-tailed) test or Fisher's exact test, where appropriate. LNα3, laminin α3; LNγ2, laminin γ2; M, male; F, female; T, tumor; B-type, basement membrane type; C-type, cytoplasmic type; M-type, mixed type; M, male; F, female.